Alka Khera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alka Khera has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Shannon B. Juengst
Brain Injury Research Center, The Institute for Rehabilitation Research Memorial Hermann Houston Texas USA
3 shared publications Maria Boix Braga
Baylor Scott & White
2 shared publications- Marlene Vega
UT Southwestern Medical Center University of Texas Medical Branch
2 shared publications - Trung Nguyen
O’Donnell Brain Institute
2 shared publications Alexandra B. Holland
Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication- Alexandra Holland
Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publication
Latest Publications
- Open Access
- 4 September 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 50, 101222
Three versus six sessions of problem-solving training with or without boosters for care partners of adults with dementia (CaDeS): a randomised controlled optimization trial
- 4 September 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 50, 101222
Open AccessThree versus six sessions of problem-solving training with or without boosters for care partners of adults with dementia (CaDeS): a randomised controlled optimization trial
- 1 May 2025
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 38 (2) , 43-49
The Clinical Value of NeuroQuant Hippocampal Volumes and Hippocampal Occupancy Scores in an Academic Medical Center Memory Clinic
Background: NeuroQuant volumetric data proposes to assist clinical diagnoses of mild cognitive impairment (MCI) and Alzheimer disease (AD) through normative hippocampal volume measurements (HVs) and hippocampal occupancy scores (HOCs). We investigated the diagnostic utility of NeuroQuant HVs and HOCs within an academic memory disorders clinic. Methods: Participants (n = 181) underwent neurologic examination, MRI with NeuroQuant, and neuropsychological assessment. Clinical diagnoses included subjective cognitive concerns (n = 39), non-amnestic MCI (n = 33), amnestic MCI (n = 74), AD (n = 35). Objective memory impairment (n = 125) was determined using actuarial criteria (≥2 memory measures ≤1.5 SD below the mean) for each participant. Differences in HVs and HOCs were assessed using ANOVA and χ2, while Pearson correlations examined their relationship with the California Verbal Learning Test-2nd Edition (CVLT-II). Receiver operator characteristic curves were used to calculate sensitivity, specificity, predictive values, Youden’s Index, and predictive summary index scores. Results: Participants with amnestic MCI, AD, and objective memory impairment had lower HVs and HOCs and a higher frequency of hippocampal atrophy (≤5th percentile) than participants with subjective cognitive concerns, non-amnestic MCI, and no objective memory impairment (P ’s r = 0.20–0.44). Discussion: NeuroQuant HVs and HOCs were lower in participants with amnestic MCI, AD, and memory impairment, but had poor sensitivity and specificity to predict memory impairment, and only a modest association with measurable memory impairment. These measures should be used cautiously as supporting diagnostic tools.
- 1 May 2025
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 38 (2) , 43-49
The Clinical Value of NeuroQuant Hippocampal Volumes and Hippocampal Occupancy Scores in an Academic Medical Center Memory Clinic
Background: NeuroQuant volumetric data proposes to assist clinical diagnoses of mild cognitive impairment (MCI) and Alzheimer disease (AD) through normative hippocampal volume measurements (HVs) and hippocampal occupancy scores (HOCs). We investigated the diagnostic utility of NeuroQuant HVs and HOCs within an academic memory disorders clinic. Methods: Participants (n = 181) underwent neurologic examination, MRI with NeuroQuant, and neuropsychological assessment. Clinical diagnoses included subjective cognitive concerns (n = 39), non-amnestic MCI (n = 33), amnestic MCI (n = 74), AD (n = 35). Objective memory impairment (n = 125) was determined using actuarial criteria (≥2 memory measures ≤1.5 SD below the mean) for each participant. Differences in HVs and HOCs were assessed using ANOVA and χ2, while Pearson correlations examined their relationship with the California Verbal Learning Test-2nd Edition (CVLT-II). Receiver operator characteristic curves were used to calculate sensitivity, specificity, predictive values, Youden’s Index, and predictive summary index scores. Results: Participants with amnestic MCI, AD, and objective memory impairment had lower HVs and HOCs and a higher frequency of hippocampal atrophy (≤5th percentile) than participants with subjective cognitive concerns, non-amnestic MCI, and no objective memory impairment (P ’s r = 0.20–0.44). Discussion: NeuroQuant HVs and HOCs were lower in participants with amnestic MCI, AD, and memory impairment, but had poor sensitivity and specificity to predict memory impairment, and only a modest association with measurable memory impairment. These measures should be used cautiously as supporting diagnostic tools.
- Open Access
- 19 January 2024
- Published by Springer Nature in Research Square
Factor Structure of the Multidimensional Health Perceptions Questionnaire in English- and Spanish-speakers
Objective: To determine the factor structure of the Multidimensional Health Perceptions Questionnaire (MHPQ), a self-reported multidimensional assessment of health perceptions, in English-speakers and Spanish-speakers in the U.S with and without various health conditions (general population). Methods: The MHPQ previously demonstrated excellent content validity (content validity index=98.1%) and conceptual equivalence in English and Spanish, with a reading grade level of th grade in both languages. We administered the original 93-item MHPQ as an anonymous survey (REDCap™) to participants in the general population (items rated on a 1=Strongly disagree to 5=Strongly agree response scale). Results: N=357 participants completed the MHPQ (n=331 English, n=26 Spanish). The sample was 74.2% women, 18-82 years old, 24.1% Hispanic/Latino, predominantly White (68.9%), and highly educated (52.1% with at least an Associate degree). Exploratory Factor Analysis resulted in 65 final items with a multidimensional structure and good internal consistency reliabilities, with the following seven health perceptions domains (% variance, Cronbach’s α): Anticipated Discrimination and Judgement (18.9%, α=.92); Spiritual Health Beliefs (8.6%, α=.89); Social and Emotional Well-being (5.5%, α=.71); Confidence in Healthcare Providers and Medicine (3.5%, α=.85); Health Self-Efficacy (2.9%, α=.79); Trust in Social Health Advice (2.8%, α=.74); and Health Literacy (2.2%, α=.86). Conclusions: Results suggest that the MHPQ may be a valid and reliable measure for comprehensively characterizing health beliefs in the general population. Future work should validate the MHPQ in specific populations.
- 19 January 2024
- Published by Springer Nature in Research Square
Open AccessFactor Structure of the Multidimensional Health Perceptions Questionnaire in English- and Spanish-speakers
Objective: To determine the factor structure of the Multidimensional Health Perceptions Questionnaire (MHPQ), a self-reported multidimensional assessment of health perceptions, in English-speakers and Spanish-speakers in the U.S with and without various health conditions (general population). Methods: The MHPQ previously demonstrated excellent content validity (content validity index=98.1%) and conceptual equivalence in English and Spanish, with a reading grade level of th grade in both languages. We administered the original 93-item MHPQ as an anonymous survey (REDCap™) to participants in the general population (items rated on a 1=Strongly disagree to 5=Strongly agree response scale). Results: N=357 participants completed the MHPQ (n=331 English, n=26 Spanish). The sample was 74.2% women, 18-82 years old, 24.1% Hispanic/Latino, predominantly White (68.9%), and highly educated (52.1% with at least an Associate degree). Exploratory Factor Analysis resulted in 65 final items with a multidimensional structure and good internal consistency reliabilities, with the following seven health perceptions domains (% variance, Cronbach’s α): Anticipated Discrimination and Judgement (18.9%, α=.92); Spiritual Health Beliefs (8.6%, α=.89); Social and Emotional Well-being (5.5%, α=.71); Confidence in Healthcare Providers and Medicine (3.5%, α=.85); Health Self-Efficacy (2.9%, α=.79); Trust in Social Health Advice (2.8%, α=.74); and Health Literacy (2.2%, α=.86). Conclusions: Results suggest that the MHPQ may be a valid and reliable measure for comprehensively characterizing health beliefs in the general population. Future work should validate the MHPQ in specific populations.
- 1 October 2022
- Published by SLACK, Inc. in Psychiatric Annals
- Vol. 52 (10) , 404-409
Evidence-Based Evaluation and Management of Cognitive Impairment in Dementia With Lewy Bodies
Dementia is a functional decline due to cognitive impairment, and its presence is required to make a diagnosis of dementia with Lewy bodies (DLB). Evaluation and management of cognitive impairment in DLB is complex and requires consideration of cognitive fluctuations as well as motor and behavioral symptoms. This article reviews the literature surrounding evaluation and management of cognitive impairment in DLB, highlighting the specific cognitive profile typically seen in early DLB as well as the available evidence for management of these symptoms. There are several pharmacological and nonpharmacological treatment strategies that are currently under investigation, and these are reviewed as well. [Psychiatr Ann. 2022;52(10):404–409.]
- 1 October 2022
- Published by SLACK, Inc. in Psychiatric Annals
- Vol. 52 (10) , 404-409
Evidence-Based Evaluation and Management of Cognitive Impairment in Dementia With Lewy Bodies
Dementia is a functional decline due to cognitive impairment, and its presence is required to make a diagnosis of dementia with Lewy bodies (DLB). Evaluation and management of cognitive impairment in DLB is complex and requires consideration of cognitive fluctuations as well as motor and behavioral symptoms. This article reviews the literature surrounding evaluation and management of cognitive impairment in DLB, highlighting the specific cognitive profile typically seen in early DLB as well as the available evidence for management of these symptoms. There are several pharmacological and nonpharmacological treatment strategies that are currently under investigation, and these are reviewed as well. [Psychiatr Ann. 2022;52(10):404–409.]
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Screening for familial hypercholesterolaemia; extending a role for blood programs in promoting public health
Background: Familial hypercholesterolaemia (FH) is a genetic disorder characterized by high levels of cholesterol with evidence of coronary arterial disease at an early age. The prevalence of FH has been recently reported as 1/200 to 1/250 in the general population and although early identification and treatment is recommended (2019 ESC/EAS Guidelines for the Management of Dyslipidaemias), the disorder is largely underdiagnosed in asymptomatic individuals.1 A number of blood programs has recognised the opportunity that blood donation provides to identify ostensibly healthy individuals who might be unaware of risks to their health. These programs have included, along with mandated serological testing, such assays as non-fasting total cholesterol (TC) and haemoglobin A1C. They have also taken steps to notify individuals whose results suggest risk for cardiovascular disease or diabetes. Purpose: Since our blood donation program has a long history of providing donors information about their TC, we tested whether some donors with elevated TC met the criteria for FH. Methods: We reviewed unlinked total non-fasting cholesterol results from volunteers donating between 2015 and June 2019. Cholesterols were measured on a chemistry analyzer system (Beckman Coulter AU680) on residual blood after routine testing for infectious disease markers. For volunteers donating more than once, we included only their highest TC recording. TC was classified by American Heart Association (AHA) 2020 Goal Metrics as high, if ≥240 mg/dL (6.2 mmol/L) in donors ≥20 years of age and ≥200 (5.1 mmol/L) in donors <20 years of age. 2 We applied the United States Center for Disease Control Cooperative MEDPED diagnostic criteria for FH. Using these criteria, FH is diagnosed when TC exceeds 270 mg/dL (7.0 mmol/L) in individuals less than 20, 290 mg/dL (7.5 mmol/L) in individuals 20 to 29, 340 mg/dL (8.8 mmol/L) in individuals 30 to 39, and 360 mg/dL (9.3 mmol/L) in individuals 40 years of age and older. 3 Results: There were 432,389 unique donors during the study period. The overall prevalence of high cholesterol, 11.1% and the prevalence of FH 0.24% are similar to published data for the general population. As shown in the table, the prevalence of FH was highest in blood donors 20 to 29 years of age and was lower in those over 30 years, while the prevalence of high TC was higher in older age groups. Conclusion: There is a subset of blood donors, at all ages who can be identified as satisfying familial hypercholesterolaemia criteria that could benefit from additional evaluation and family screening. A sizeable proportion of blood donors have high cholesterol despite not having FH. Funding Acknowledgement: Type of funding sources: None.
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessScreening for familial hypercholesterolaemia; extending a role for blood programs in promoting public health
Background: Familial hypercholesterolaemia (FH) is a genetic disorder characterized by high levels of cholesterol with evidence of coronary arterial disease at an early age. The prevalence of FH has been recently reported as 1/200 to 1/250 in the general population and although early identification and treatment is recommended (2019 ESC/EAS Guidelines for the Management of Dyslipidaemias), the disorder is largely underdiagnosed in asymptomatic individuals.1 A number of blood programs has recognised the opportunity that blood donation provides to identify ostensibly healthy individuals who might be unaware of risks to their health. These programs have included, along with mandated serological testing, such assays as non-fasting total cholesterol (TC) and haemoglobin A1C. They have also taken steps to notify individuals whose results suggest risk for cardiovascular disease or diabetes. Purpose: Since our blood donation program has a long history of providing donors information about their TC, we tested whether some donors with elevated TC met the criteria for FH. Methods: We reviewed unlinked total non-fasting cholesterol results from volunteers donating between 2015 and June 2019. Cholesterols were measured on a chemistry analyzer system (Beckman Coulter AU680) on residual blood after routine testing for infectious disease markers. For volunteers donating more than once, we included only their highest TC recording. TC was classified by American Heart Association (AHA) 2020 Goal Metrics as high, if ≥240 mg/dL (6.2 mmol/L) in donors ≥20 years of age and ≥200 (5.1 mmol/L) in donors <20 years of age. 2 We applied the United States Center for Disease Control Cooperative MEDPED diagnostic criteria for FH. Using these criteria, FH is diagnosed when TC exceeds 270 mg/dL (7.0 mmol/L) in individuals less than 20, 290 mg/dL (7.5 mmol/L) in individuals 20 to 29, 340 mg/dL (8.8 mmol/L) in individuals 30 to 39, and 360 mg/dL (9.3 mmol/L) in individuals 40 years of age and older. 3 Results: There were 432,389 unique donors during the study period. The overall prevalence of high cholesterol, 11.1% and the prevalence of FH 0.24% are similar to published data for the general population. As shown in the table, the prevalence of FH was highest in blood donors 20 to 29 years of age and was lower in those over 30 years, while the prevalence of high TC was higher in older age groups. Conclusion: There is a subset of blood donors, at all ages who can be identified as satisfying familial hypercholesterolaemia criteria that could benefit from additional evaluation and family screening. A sizeable proportion of blood donors have high cholesterol despite not having FH. Funding Acknowledgement: Type of funding sources: None.
- Open Access
- 24 September 2022
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 6 (1) , 1-8
Development of the multidimensional health perceptions questionnaire in English and Spanish
Purpose: To develop the novel multidimensional health perceptions questionnaire (MHPQ), a self-reported assessment of health perceptions inclusive of (1) individuals beliefs about the causes and consequences of health conditions, benefits and barriers to maintaining and improving health, ability to accomplish health-related goals and control health circumstances, and the role of God and/or spirituality in health and healthcare, (2) anticipated discrimination in the healthcare systems, and (3) trust in healthcare providers and medicine, illustrated in our newly proposed Multidimensional Health Perceptions Conceptual Model. Methods: We developed an initial MHPQβ item set, corresponding to domains of our conceptual model, using a patient-centered outcomes development approach. This include literature review, expert and end-user feedback, translation and language validation (specifically to Latin American Spanish), and cognitive interviewing. Results: The initial 104 items of MHPQβ had excellent content validity, with a Content Validity Index of 98.1%. After expert (n = 13) feedback, translation and language validation, and cognitive interviewing among community-dwelling English-speakers (n = 5) and Spanish-speakers (n = 4), the final MHPQβ comprised 93 items rated on a five-point agreement scale (1 = Strongly disagree to 5 = Strongly agree), with a reading grade level of 6th grade in English and 8th grade in Spanish. Conclusion: The MHPQβ is a promising tool to assess individuals’ health perceptions. It has excellent content validity and good reading accessibility. Future work will establish the factor structure and final item set of the MHPQ.
- 24 September 2022
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 6 (1) , 1-8
Open AccessDevelopment of the multidimensional health perceptions questionnaire in English and Spanish
Purpose: To develop the novel multidimensional health perceptions questionnaire (MHPQ), a self-reported assessment of health perceptions inclusive of (1) individuals beliefs about the causes and consequences of health conditions, benefits and barriers to maintaining and improving health, ability to accomplish health-related goals and control health circumstances, and the role of God and/or spirituality in health and healthcare, (2) anticipated discrimination in the healthcare systems, and (3) trust in healthcare providers and medicine, illustrated in our newly proposed Multidimensional Health Perceptions Conceptual Model. Methods: We developed an initial MHPQβ item set, corresponding to domains of our conceptual model, using a patient-centered outcomes development approach. This include literature review, expert and end-user feedback, translation and language validation (specifically to Latin American Spanish), and cognitive interviewing. Results: The initial 104 items of MHPQβ had excellent content validity, with a Content Validity Index of 98.1%. After expert (n = 13) feedback, translation and language validation, and cognitive interviewing among community-dwelling English-speakers (n = 5) and Spanish-speakers (n = 4), the final MHPQβ comprised 93 items rated on a five-point agreement scale (1 = Strongly disagree to 5 = Strongly agree), with a reading grade level of 6th grade in English and 8th grade in Spanish. Conclusion: The MHPQβ is a promising tool to assess individuals’ health perceptions. It has excellent content validity and good reading accessibility. Future work will establish the factor structure and final item set of the MHPQ.
- Open Access
- 5 June 2022
- Published by MDPI AG in Geriatrics
- Vol. 7 (3) , 61
Cognitive Decline in Older People with Multiple Sclerosis—A Narrative Review of the Literature
Several important questions regarding cognitive aging and dementia in older people with multiple sclerosis (PwMS) are the focus of this narrative review: Do older PwMS have worse cognitive decline compared to older people without MS? Can older PwMS develop dementia or other neurodegenerative diseases such as Alzheimer’s disease (AD) that may be accelerated due to MS? Are there any potential biomarkers that can help to determine the etiology of cognitive decline in older PwMS? What are the neural and cellular bases of cognitive aging and neurodegeneration in MS? Current evidence suggests that cognitive impairment in MS is distinguishable from that due to other neurodegenerative diseases, although older PwMS may present with accelerated cognitive decline. While dementia is prevalent in PwMS, there is currently no consensus on defining it. Cerebrospinal fluid and imaging biomarkers have the potential to identify disease processes linked to MS and other comorbidities—such as AD and vascular disease—in older PwMS, although more research is required. In conclusion, one should be aware that multiple underlying pathologies can coexist in older PwMS and cause cognitive decline. Future basic and clinical research will need to consider these complex factors to better understand the underlying pathophysiology, and to improve diagnostic accuracy.
- 5 June 2022
- Published by MDPI AG in Geriatrics
- Vol. 7 (3) , 61
Open AccessCognitive Decline in Older People with Multiple Sclerosis—A Narrative Review of the Literature
Several important questions regarding cognitive aging and dementia in older people with multiple sclerosis (PwMS) are the focus of this narrative review: Do older PwMS have worse cognitive decline compared to older people without MS? Can older PwMS develop dementia or other neurodegenerative diseases such as Alzheimer’s disease (AD) that may be accelerated due to MS? Are there any potential biomarkers that can help to determine the etiology of cognitive decline in older PwMS? What are the neural and cellular bases of cognitive aging and neurodegeneration in MS? Current evidence suggests that cognitive impairment in MS is distinguishable from that due to other neurodegenerative diseases, although older PwMS may present with accelerated cognitive decline. While dementia is prevalent in PwMS, there is currently no consensus on defining it. Cerebrospinal fluid and imaging biomarkers have the potential to identify disease processes linked to MS and other comorbidities—such as AD and vascular disease—in older PwMS, although more research is required. In conclusion, one should be aware that multiple underlying pathologies can coexist in older PwMS and cause cognitive decline. Future basic and clinical research will need to consider these complex factors to better understand the underlying pathophysiology, and to improve diagnostic accuracy.
- 1 November 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (11) , 106029
Two Unique Mutations in HTRA1-Related Cerebral Small Vessel Disease in North America and Africa and Literature Review
- 1 November 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (11) , 106029
Two Unique Mutations in HTRA1-Related Cerebral Small Vessel Disease in North America and Africa and Literature Review